Background-Few published data describe long-term survival of dialysis patients undergoing surgical versus percutaneous coronary revascularization in the era of drug-eluting stents (DES). Methods and Results-Using United States Renal Data System data, we identified 23 033 dialysis patients who underwent coronary revascularization (6178 coronary artery bypass grafting, 5011 bare metal stents, 11 844 DES) from 2004 to 2009. Revascularization procedures decreased from 4347 in 2004 to 3344 in 2009. DES use decreased by 41% and bare metal stent use increased by 85% from 2006 to 2007. Long-term survival was estimated by the Kaplan-Meier method,
R andomized studies have compared long-term outcomes of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) with bare metal stents (BMS) in nondialysis patients, yielding concordant results: comparable rates of death and myocardial infarction but higher rates of repeat revascularization with BMS. 1, 2 Since US Food and Drug Administration approval in 2003, drug-eluting stents (DES) have been used for the majority of PCI procedures in the United States owing to the reduced incidence of in-stent restenosis and repeat revascularization, but DES have failed to demonstrate any survival advantage relative to BMS. 3 Improved outcomes associated with DES have led to their evaluation in randomized studies comparing outcomes relative to CABG in high-risk patient subsets for whom surgical revascularization was traditionally recommended. 4 However, patients with end-stage renal disease (ESRD) undergoing maintenance dialysis have been excluded from any randomized evaluation of the comparative efficacy of coronary revascularization strategies.
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Cardiac disease is a major cause of mortality among dialysis patients; according to recent estimates, it accounts for ≈38% of all-cause deaths, and ≈13% of cardiac deaths are ascribed to myocardial infarction. 5 Arguably, dialysis patients constitute one of the highest-risk groups in terms of mortality associated with coronary revascularization. Herzog et al 6 reported 2-year survival rates of 56% and 48% after CABG and PCI with BMS, respectively. Hemmelgarn et al 7 noted that 8-year mortality rates after coronary revascularization were nearly 2-fold higher among dialysis than nondialysis patients: 86% versus 45% after CABG and 80% versus 41% after PCI. More recently, Tsai et al 8 reported 30-month mortality rates of 52% for long-term dialysis patients undergoing PCI from 2004 to 2007.
In the earliest era of PCI, percutaneous transluminal coronary angioplasty and CABG from 1978 to 1995 were compared by use of United States Renal Data System (USRDS) data. Despite higher in-hospital mortality rates with CABG versus percutaneous transluminal coronary angioplasty (12.5% versus 5.4%), all-cause mortality rates at 1 year were comparable and 2-year survival was more favorable after surgical revascularization. 9 In the era of BMS, comparative survival after coronary revascularization was readdressed with the use of USRDS data from 1995 to 1998. 6 Again, despite 2-fold-higher in-hospital mortality with CABG (8.6% versus 4.1% for BMS), improved survival with CABG was noted within 1 year after the index procedure.
The advent of DES renewed optimism for the potential of improving PCI-related outcomes in dialysis patients. In a meta-analysis of 7 studies, Abdel-Latif et al 10 reported a significant reduction in repeat revascularization and a trend toward reduced mortality with DES compared with BMS in dialysis patients. In a large cohort of US Medicare patients including 5182 dialysis patients, Tsai et al 8 reported a statistically significant mortality benefit associated with DES compared with BMS. Conversely, high in-hospital mortality rates after CABG continue to remain a formidable challenge 11 ; techniques such as off-pump surgery have demonstrated only a modest impact on short-term mortality. 12 Thus, the optimal option for coronary revascularization in dialysis patients remains a matter of debate. Nevis et al 13 concluded from an exploratory meta-analysis of 17 studies evaluating CABG versus PCI that existing data are inadequate to make a determination on the optimal strategy of coronary revascularization for dialysis patients. Using USRDS data, we sought to evaluate long-term survival rates and the probability of repeat coronary revascularization of dialysis patients undergoing surgical and percutaneous coronary revascularization in the contemporary era and to identify independent predictors of mortality.
Methods
Using the USRDS database (n=546 160 eligible dialysis patients, 2004-2009), this retrospective study identified dialysis patients who were hospitalized for their first coronary revascularization procedure after initiation of renal replacement therapy (n=23 033). Eligible patients had received renal replacement therapy for ≥90 days before revascularization. Through the use of Medicare claims, all patients undergoing CABG without concomitant valve surgery or PCI with DES or BMS placement between January 1, 2004, and December 31, 2009, and followed up through December 31, 2010, were identified. Using the codes listed in Table I in the online-only Data Supplement, we identified 6178 CABG patients, 5011 BMS patients, and 11 844 DES patients in the study period. Patients undergoing percutaneous transluminal coronary angioplasty alone were not included in the analysis. Patients who underwent both surgical and percutaneous intervention during the same hospital stay were also excluded.
Survival was determined from the time of revascularization to death or censoring. Patients who underwent renal transplantation or were lost to follow-up before December 31, 2010, were censored. Death was identified from the USRDS database. Cause-specific mortality was determined from the Centers for Medicare & Medicaid ESRD Death Notification (form CMS-2746). Long-term survival was estimated with the Kaplan-Meier method, with the log-rank test used to compare differences in survival. Comorbidity-adjusted Cox proportional hazards models were used to assess the effect of comorbid conditions on survival in each revascularization cohort. Comorbid conditions studied included prior myocardial infarction; congestive heart failure; other cardiac conditions, including valvular heart disease; presence of a pacemaker and arrhythmia; prior coronary revascularization; malignancies other than skin malignancies; peripheral vascular disease; cerebrovascular accident or transient ischemic attack; chronic obstructive pulmonary disease; gastrointestinal disease; gall bladder disease; and liver disease. Cumulative probability of repeat coronary revascularization (accounting for the competing risk of death) was calculated with unadjusted, nonparametric methods. 14 The χ 2 test was used to detect differences between proportions. All reported P values are 2-sided. All statistical analyses were performed with the SAS system for Windows, version 9.2 (SAS institute, Inc). Figure 1 . During the study period, the overall number of coronary revascularization procedures decreased from 4347 in 2004 to 3344 in 2009. The annual volume of CABG procedures was similar during the study period, typically accounting for 25% to 30% of all procedures. From 2004 to 2006, DES accounted for 59% of all procedures and BMS for ≈15%. However, from 2007 to 2009, a dramatic change occurred in the pattern of stent use, with a marked decrease in the use of DES and a corresponding increase in the use of BMS. From 2006 to 2007 alone, the number of DES procedures dropped from 2494 to 1462 (a 41% reduction), whereas the number of BMS procedures increased from 606 to 1120 (an 85% increase). Preliminary data from 2010 suggest a trend toward a rebound in DES use (47% of all procedures) and a corresponding decrease in BMS use (26%).
Results
Demographic characteristics of the study group are summarized in Table 1 . Notably, a greater proportion of younger patients underwent surgical revascularization procedures than percutaneous procedures (P<0.0001). Among patients who underwent CABG with an IMG, 43% were 45 to 64 years of age, 12% were 75 to 79 years of age, and only 7% were ≥80 years of age. Among patients who underwent PCI with DES, however, 35% were 45 to 64 years of age and 31% were 65 to 74 years of age, and proportions in older age groups were relatively higher: 16% were 75 to 79 years of age and 14% were ≥80 years of age. There was a statistically significant difference in dialysis modality between groups; peritoneal dialysis was more common in the CABG than in the PCI group (P=0.03). Diabetes mellitus as cause of renal failure was similar (58.2% versus 57.1%; P=0.13), but a greater proportion of patients in the PCI group than in the CABG group were likely to have hypertension as the primary cause of renal failure (P=0.016). Proportions of patients with congestive heart failure (63.8% versus 63.5%; P=0.67) and diabetes mellitus (76.7% versus 77.1%; P=0.61) were comparable in the CABG with an IMG group and the DES group. Among patients who underwent CABG without an IMG, the prevalence of congestive heart failure was slightly higher and the prevalence of diabetes mellitus was somewhat lower than in the other revascularization groups.
Kaplan-Meier estimates for all-cause survival for each revascularization modality were individually constructed (Figure 2A-2D ). Of note, 1-year survival was significantly higher in 2009 than in 2004 for CABG (P=0.002 by log-rank test) and DES (P=0.015) patients but not for BMS patients (63.4% in 2004 versus 62.3% in 2009; P=0.57). Thus, there was evidence of improvement in outcomes for CABG and DES during the study period. Surgical revascularization carried a significant initial mortality hazard. In-hospital death was 8.2% for patients undergoing CABG (Figure 2A ); this rate was lower for patients undergoing revascularization with an IMG (7.8%) than for patients undergoing revascularization without an IMG (9.3%; P=0.059). Survival rates at 1 month were 90% and 87% for CABG with and without an IMG, respectively ( Figure 2B ). At 12 months after the index revascularization, all-cause survival for CABG with an IMG was 72% versus 64% for CABG without an IMG. At 2 years, patients who underwent CABG with an IMG had a significant survival advantage (59.6%) compared with patients who underwent CABG without an IMG (50.6%; P<0.0001), a difference that persisted in longer-term follow-up. For patients undergoing percutaneous revascularization, in-hospital mortality was 2.7% for DES and 4.9% for BMS (P<0.0001). Thus, in-hospital mortality was significantly higher in the context of surgical versus percutaneous revascularization (8.2% versus 3.4%; P<0.0001). Survival rates at 1 month were 94% for DES patients, and subsequent all-cause survival was 71% at 1 year and 53% at 2 years ( Figure 2C ). Survival rates for BMS patients were 63% at 1 year and 48% at 2 years ( Figure 2D ).
Of the nearly 14 000 deaths identified, more than half were attributable to cardiovascular causes (all, 55%; CABG, 53%; DES, 56%; BMS, 57%; Table 2 ), and ≈10% were attributable to infection (all, 9.6%; CABG, 12%; DES, 9.1%; BMS, 8.1%). Thus, infection as a cause of death was more prevalent in the CABG than the PCI cohort. Notably, withdrawal from dialysis accounted for 7.4% of all deaths. Almost 40% of the study cohort were censored before death: 91% as a result of the end of the follow-up period, 7% as a result of a change in type of renal replacement therapy (including 2% who underwent kidney transplantation), and the remaining 2% as a result of changes in primary payer or eligibility status.
We created separate Cox models to assess independent predictors of mortality for each revascularization modality ( Table 3 ). Not surprisingly, increasing age, increasing dialysis duration, and comorbid conditions (in particular, congestive heart failure, chronic obstructive pulmonary disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease) were independently predictive of increased mortality after both surgical and percutaneous revascularization. Black race was associated with a significantly reduced hazard of mortality in all 3 groups: CABG: hazard ratio (HR), 0.88 (P=0.0009); DES: HR, 0.87 (P<0.0001); and BMS; HR, 0.86 (P=0.0006). Interestingly, diabetes mellitus was an independent predictor of mortality in the BMS group (HR, 1.18; 95% confidence interval, 1.07-1.31) but not in the CABG (HR, 1.07; 95% confidence interval, 0.97-1.1) or DES (HR, 1.03; 95% confidence interval, 0.96-1.10) group. Among patients undergoing surgical revascularization, use of an IMG was independently associated with a reduced hazard of long-term mortality (HR, 0.83; 95% confidence interval, 0.77-0.90; P<0.0001).
We further evaluated repeat coronary revascularization (CABG or PCI), accounting for the competing risk of death among patients undergoing surgical and percutaneous revascularization. Of 6178 patients who originally underwent CABG, 773 (12.5%) underwent a repeat coronary revascularization procedure; of 11 844 patients who originally received DES, 3404 (28.7%) underwent a repeat procedure; and of 5011 who originally received BMS, 1246 (24.9%) underwent a repeat procedure. Figure 3 shows the distribution of types of repeat procedures performed given the original procedure. The most common type of repeat procedure was DES (49% of CAB patients, 58% of DES patients, and 41% of BMS patients). The cumulative probability of repeat revascularization was 1.4% at 1 month, 3.8% at 6 months, 6.0% at 1 year, 9.9% at 2 years, 12.7% at 3 years, and 15.7% at 5 years for CABG. Corresponding estimates for DES were 5.7%, 13.6%, 19.1%, 25.1%, 28.8%, and 32.5%, and for BMS, 5.0%, 14.1%,18.3%, 23.2%, 26.0%, and 29.0%. Importantly, the cumulative probability of repeat revascularization was similar in DES and BMS patients at all time intervals studied.
We attempted to quantify the variation in the distribution of type of revascularization procedures performed on a procedure center level. We counted the number of to 50% of revascularization procedures were CABGs. The distribution in 2009 was similar but appeared to be moving closer to the distribution in 2004 to 2005. In summary, for the middle half of centers, CABGs made up between one-fourth and one-half of revascularization procedures, and for most centers, CABGs made up between 15% and 60%. Therefore, important variations in distribution of revascularization procedures occurred, although it could be assumed that patient selection was relatively similar for most centers, with only a few outlier centers. 
Discussion
These observational data attempt to bridge a gap in the existing literature pertaining to the choice of the optimal revascularization strategy in dialysis patients in the contemporary era. Data from a large, representative sample of dialysis patients demonstrate the tradeoffs pertinent to clinical decisions on the optimal revascularization strategy in this high-risk population: high in-hospital mortality rates but superior long-term survival (especially with use of IMGs) with surgical revascularization and higher short-term survival but higher probability of repeat revascularization with percutaneous revascularization using BMS and DES. Importantly, survival rates in the surgical and DES cohorts (but not in the BMS cohort) have improved somewhat in the contemporary era. We found 2-year survival rates after CABG with an IMG, DES, and BMS of 60%, 53%, and 48%, respectively, from 2004 to 2009 compared with 56% and 48% after CABG and BMS, respectively, from 1995 to 1998. 6 The shift in patterns of coronary revascularization among dialysis patients is also relevant. The decrement in DES use after 2006, with a proportional increase in BMS use (Figure 1) , coincides with trends toward reduced PCI volume nationally since 2004 15 and, in particular, reduced DES volume after the emergence of concerns about stent thrombosis. 16 Multiple contemporaneous publications addressed concerns pertaining to the use of DES, including off-label use, the incidence of stent thrombosis relative to BMS, and especially the unique phenomenon of late stent thrombosis. 17, 18 National trends since 2010 have subsequently demonstrated an upswing in DES use.
Previous studies have compared outcomes of CABG and DES in dialysis patients with conflicting results. Manabe et al 19 studied 28 CABG and 18 DES patients and reported similar 2-year survival in the 2 groups but significantly lower rates of major adverse cardiac outcomes in the surgical group. In these studies, short-term mortality rates associated with CABG were significantly lower than average, suggesting that these were selected patients from single centers, thus limiting the generalizability of the results. Ashrith et al 21 evaluated patients with chronic kidney disease and multivessel coronary artery disease undergoing coronary revascularization, including 87 ESRD patients (54 CABG, 33 DES). The authors reported comparable 30-day survival rates in the 2 groups for dialysis patients but a trend toward improved survival with CABG for chronic kidney disease patients. In summary, the theme from prior studies has been that in dialysis patients, the initial advantage of PCI, although longer-lasting with DES than with BMS 6 and percutaneous transluminal coronary angioplasty, 9 is generally overtaken by surgical revascularization after ≈18 months. As we were preparing the revised version of this article, Chang et al 22 published a study using USRDS data to examine the comparative effectiveness of multivessel PCI versus CABG in a propensity model. The overall survival data are concordant with the data we report, but we believe that the structure of the USRDS database, which includes no data on coronary angiography, precludes valid assessment of the comparative effectiveness of revascularization strategies. Significant selection biases germane to the choice of revascularization procedures in actual clinical practice are contingent on variables that cannot be retrospectively measured or reconciled accurately with an administrative database (angiographic characteristics, including target vessel diameter, lesion complexity, and coronary calcification; left ventricular ejection fraction; estimation of bleeding risk; surgical expertise; etc). Thus, a direct comparison of survival between CABG and DES (or a comparative effectiveness analysis) was not judged to be reasonable and could potentially be misleading with the use of these observational data. Instead, our study describes survival data for the revascularization cohorts and provides a national benchmark pertaining to short-term and long-term outcomes for each revascularization strategy to guide the clinician.
Reasons underlying an apparent lack of long-term benefit of PCI with DES in the dialysis population compared with non-ESRD patients bear emphasis. In particular, it is notable that the probability of repeat revascularization for DES was comparable to the probability for BMS at all intervals studied among dialysis patients; this finding is contrary to findings in non-ESRD patients but consistent with studies performed in Japan reporting rates of angiographically detected restenosis in dialysis patients receiving BMS (24% to 43%) or DES (22% to 31%). [23] [24] [25] [26] Improved outcomes associated with DES in non-ESRD patients cannot be automatically extrapolated to the ESRD population because of qualitative differences in morphological and physiological characteristics of coronary lesions in ESRD patients. Atherosclerotic plaques in ESRD patients are characterized by severe calcification and medial thickening, 27 resulting in a higher proportion of angiographically complex lesions (type B2/C), predicting lower procedural success with PCI. 28 In addition, the rate of neointimal hyperplasia and late lumen loss is higher in ESRD patients, resulting in an almost 4-fold-higher risk of in-stent restenosis and a corresponding higher rate of adverse cardiac outcomes, including mortality. 28 Importantly, the pattern of restenosis is frequently diffuse (versus focal in non-ESRD patients), which may be associated with higher risk of repeat revascularization. 26 Recent data from a multicenter study in Japan using sirolimuseluting stents emphasize the >2-fold-higher rates of target lesion revascularization and >5-fold-greater risk of cardiac mortality after adjustment for baseline characteristics and procedural characteristics in patients undergoing hemodialysis versus those not undergoing dialysis. 29 Hemodialysis has consistently been shown to be an independent risk factor for in-stent restenosis after the placement of stents eluting sirolimus 28 and paclitaxel, 30 both first-generation DES platforms. Finally, the pathophysiological factors underlying the process of accelerated atherosclerosis also predispose to stent thrombosis, a phenomenon of particular concern with DES, 16, 31 which could also result in higher rates of myocardial infarction and mortality.
The relatively higher short-term and long-term mortality of dialysis patients undergoing BMS placement relative to DES and CABG surgery is underscored in this study and needs to be reconciled. This observation could reflect selection bias inherent in observational data; ie, patients chosen to undergo BMS placement may have conditions (eg, bleeding diathesis, noncardiac surgery) that preclude DES placement and affect survival. An alternative explanation could relate to in-stent restenosis and the resultant need for repeat revascularization with BMS. (However, our data on repeat revascularization do not support this idea.) In a study using a strategy of routine coronary angiography to detect in-stent restenosis in a nondialysis population, Schühlen et al 32 showed that mortality rates in 4 years of follow-up were higher in patients with in-stent restenosis than in patients without in-stent stenosis. As noted above, some data indicate in-stent restenosis in as many as 40% of BMS in dialysis patients, and importantly, the diffuse pattern of restenosis in this population likely portends a higher risk of repeat revascularization. 26 A recent study by Sakakibara et al 33 from a single center in Japan provided encouraging data showing that everolimus-eluting stents markedly reduced rates of angiographic in-stent restenosis with associated modest reduction in major adverse cardiac events relative to sirolimus-eluting stents, likely related to a combination of reduced inflammation associated with the platform, thinner stent struts, and more rapid endothelialization. Possibly, newer generations of DES may change the panorama of coronary revascularization in dialysis patients in the future.
The data from this study should be interpreted in the context of important limitations. These observational data have the inherent potential for selection bias and unmeasured confounders and should therefore be considered exploratory and hypothesis generating. To derive conclusions directly applicable to clinical practice, a prospective randomized study would be the ideal method of evaluating comparative outcomes of dialysis patients undergoing PCI with DES versus CABG surgery. Because our data are derived from an administrative database, prognostically relevant clinical information pertaining to angiographic characteristics, lesion complexity, and left ventricular ejection fraction is not available, as previously described. Similarly, data on the use of adjunctive pharmacological therapy and complications thereof, particularly any associated risk of bleeding, and platform of DES used are not available. Although the probability of repeat revascularization was studied, we were unable to discern target lesion, target vessel revascularization, or revascularization in different coronary distributions.
Conclusions
These data illustrate a recent shift in interventional practice patterns in US dialysis patients, with a decrease in DES use and a corresponding rise in BMS use since 2006. Additionally, these data suggest that although CABG with an IMG was associated with high in-hospital mortality rates (although lower than CABG without an IMG), it was also associated with improved long-term survival in dialysis patients. DES use was associated with relatively lower in-hospital mortality but a significantly higher probability of repeat revascularization in the future. DES may be a reasonable consideration in dialysis patients in whom an IMG (typically used to bypass the left anterior descending coronary artery vascular territory) is by guest on May 1, 2017 http://circ.ahajournals.org/ not an appropriate option in the revascularization strategy or whose overall life expectancy is judged to be limited. For some patients, PCI with DES might be preferable because the higher perioperative mortality (and likely morbidity) of CABG might be judged to be an inferior choice, despite potentially superior long-term survival. The findings from this study support the recently popularized notion of adopting a heart team approach (ie, deriving input from interventional cardiologists and cardiovascular surgeons to determine an individualized, optimal approach) for coronary revascularization in dialysis patients.
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